Voyager Therapeutics (NASDAQ:VYGR) Downgraded by Zacks Investment Research to “Hold”

Voyager Therapeutics (NASDAQ:VYGRGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also recently weighed in on VYGR. Chardan Capital lifted their price objective on shares of Voyager Therapeutics from $4.00 to $6.00 in a report on Wednesday, March 9th. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, April 30th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $13.67.

Shares of VYGR stock traded down $0.73 on Friday, hitting $6.21. The company had a trading volume of 642,921 shares, compared to its average volume of 922,520. Voyager Therapeutics has a twelve month low of $2.46 and a twelve month high of $10.60. The firm has a market cap of $238.46 million, a P/E ratio of -3.30 and a beta of 1.08. The company has a 50-day moving average price of $7.51 and a 200-day moving average price of $4.70.

Voyager Therapeutics (NASDAQ:VYGRGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.19). Voyager Therapeutics had a negative net margin of 224.48% and a negative return on equity of 72.56%. As a group, sell-side analysts predict that Voyager Therapeutics will post -1.35 earnings per share for the current fiscal year.

In other news, VP Robert W. Hesslein sold 4,955 shares of the firm’s stock in a transaction that occurred on Monday, March 21st. The stock was sold at an average price of $8.29, for a total value of $41,076.95. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Robin Swartz sold 4,413 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, March 21st. The stock was sold at an average price of $8.29, for a total value of $36,583.77. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,933 shares of company stock worth $124,170. Company insiders own 25.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Belvedere Trading LLC raised its position in Voyager Therapeutics by 4.9% in the first quarter. Belvedere Trading LLC now owns 36,340 shares of the company’s stock valued at $347,000 after purchasing an additional 1,683 shares during the period. Royal Bank of Canada raised its position in Voyager Therapeutics by 160.7% in the second quarter. Royal Bank of Canada now owns 5,937 shares of the company’s stock valued at $25,000 after purchasing an additional 3,660 shares during the period. Bank of America Corp DE raised its position in Voyager Therapeutics by 34.3% in the second quarter. Bank of America Corp DE now owns 29,896 shares of the company’s stock valued at $124,000 after purchasing an additional 7,640 shares during the period. IndexIQ Advisors LLC grew its stake in shares of Voyager Therapeutics by 11.1% in the third quarter. IndexIQ Advisors LLC now owns 95,456 shares of the company’s stock valued at $251,000 after buying an additional 9,561 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $27,000. Hedge funds and other institutional investors own 46.16% of the company’s stock.

About Voyager Therapeutics (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Recommended Stories

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.